机译:通过在纳米颗粒中的PI3K / mTOR抑制剂BEZ235和索拉非尼的共同递送,可以克服肝细胞癌对索拉非尼的抗性
Bengbu Med Coll Dept Hepatobiliary Surg Affiliated Hosp 1 Bengbu Peoples R China;
Anhui Univ Sci &
Technol Med Sch Biochem Dept 168 Taifeng St Huainan Anhui Peoples R China;
Anhui Univ Sci &
Technol Med Sch Biochem Dept 168 Taifeng St Huainan Anhui Peoples R China;
Anhui Univ Sci &
Technol Med Sch Biochem Dept 168 Taifeng St Huainan Anhui Peoples R China;
Anhui Univ Sci &
Technol Med Sch Biochem Dept 168 Taifeng St Huainan Anhui Peoples R China;
Bengbu Med Coll Dept Hepatobiliary Surg Affiliated Hosp 1 Bengbu Peoples R China;
Anhui Univ Sci &
Technol Med Sch Biochem Dept 168 Taifeng St Huainan Anhui Peoples R China;
Xuzhou Med Coll Huaian Hosp Cent Lab Huaian Peoples R China;
Bengbu Med Coll Dept Hepatobiliary Surg Affiliated Hosp 1 Bengbu Peoples R China;
Hepatocellular carcinoma; BEZ235; sorafenib; PI3K; mTOR; nanoparticles; polycaprolactone; apoptosis;
机译:通过在纳米颗粒中的PI3K / mTOR抑制剂BEZ235和索拉非尼的共同递送,可以克服肝细胞癌对索拉非尼的抗性
机译:Bez235通过抑制PI3K / AKT / MTOR途径增加Sorafenib对肝细胞癌细胞的抑制作用
机译:一种新型双PI3K / mTOR抑制剂,单独,单独和索拉酮组合在肝细胞癌中的临床前疗效,CMG002
机译:口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
机译:BEZ235,PI3K / mTOR抑制剂和依维莫司,mTOR抑制剂的新型组合的临床药代动力学:I期临床研究和非临床机制评估
机译:靶向CXCR4的PLGA-PEG纳米粒封装的索拉非尼和metapristone的共同给药克服了肝癌对索拉非尼的耐药性
机译:通过重新编程肿瘤缺氧微环境,通过多功能纳米粒子共同交付Plantamajoside和Sorafenib来打击肝细胞癌的耐药性